ArticleThe Journal of clinical investigation2008
Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
Article in The Journal of clinical investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 67 citations in OpenAlex.
- MAFB: a key regulator of myeloid commitment involved in hematological diseases.Cell death discovery · 2025Review
- Unlocking the therapeutic potential of selective CDK7 and BRD4 inhibition against multiple myeloma cell growth.Haematologica · 2025Article
- Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.Haematologica · 2024Article
- Inhibition of USP10 induces myeloma cell apoptosis by promoting cyclin D3 degradation.Acta pharmacologica Sinica · 2023Article
- CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.Blood · 2023Article
- Harmol hydrochloride dihydrate induces autophagy in neuro cells and promotes the degradation of α-Syn by Atg5/Atg12-dependent pathway.Food science & nutrition · 2022Article
- Review
- LncRNA HOTAIR influences cell proliferation via miR-130b/PTEN/AKT axis in IDD.Cell cycle (Georgetown, Tex.) · 2022Article
- Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.Nature communications · 2021Article
- Suppression of the USP10/CCND1 axis induces glioblastoma cell apoptosis.Acta pharmacologica Sinica · 2021Article
- Implications of Oxidative Stress in Glioblastoma Multiforme Following Treatment with Purine Derivatives.Antioxidants (Basel, Switzerland) · 2021Article
- Phytohormone cytokinin guides microtubule dynamics during cell progression from proliferative to differentiated stage.The EMBO journal · 2020Article
- Anion exchange resins in phosphate form as versatile carriers for the reactions catalyzed by nucleoside phosphorylases.Beilstein journal of organic chemistry · 2020Article
- Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma.Cancer management and research · 2019Review
- Synthesis of a Cytokinin Linked by a Spacer to Dexamethasone and Biotin: Conjugates to Detect Cytokinin-Binding Proteins.Molecules (Basel, Switzerland) · 2016Article
- Glucose Induces Mouse β-Cell Proliferation via IRS2, MTOR, and Cyclin D2 but Not the Insulin Receptor.Diabetes · 2016Article
- A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway.Oncotarget · 2016Article
- SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway.Scientific reports · 2015Article
- DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.British journal of cancer · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
Knockout and transgenic studies in mice demonstrate that normal somatic tissues redundantly express 3 cyclin D proteins, whereas tumor cells seem dependent on a single overexpressed cyclin D. Thus, selective suppression of the individual cyclin D deregulated in a tumor represents a biologically valid approach to targeted cancer therapy. In multiple myeloma, overexpression of 1 of the cyclin D proteins is a ubiquitous feature, unifying at least 7 different initiating genetic events. We demonstrate here that RNAi of genes encoding cyclin D1 and cyclin D2 (CCND1 and CCND2, respectively) inhibits proliferation and is progressively cytotoxic in human myeloma cells. By screening a chemical library using a cell-based assay for inhibition of CCND2 trans-activation, we identified the plant cytokinin kinetin riboside as an inhibitor of CCND2 trans-activation. Kinetin riboside induced marked suppression of CCND2 transcription and rapidly suppressed cyclin D1 and D2 protein expression in primary myeloma cells and tumor lines, causing cell-cycle arrest, tumor cell-selective apoptosis, and inhibition of myeloma growth in xenografted mice. Mechanistically, kinetin riboside upregulated expression of transcription repressor isoforms of cAMP-response element modulator (CREM) and blocked both trans-activation of CCND2 by various myeloma oncogenes and cis-activation of translocated CCND1, suggesting induction of an overriding repressor activity that blocks multiple oncogenic pathways targeting cyclin D genes. These data support targeted repression of cyclin D genes as a therapeutic strategy for human malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.